Volume | 56,345 |
|
|||||
News | - | ||||||
Day High | 0.8549 | Low High |
|||||
Day Low | 0.77 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Cingulate Inc | CING | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.814 | 0.77 | 0.8549 | 0.79 | 0.79 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
172 | 56,345 | $ 0.801241 | $ 45,146 | - | 0.70 - 21.80 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:40:47 | 25 | $ 0.8183 | USD |
Cingulate Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
740.23k | 937.00k | - | 0 | -23.54M | -25.12 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cingulate News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CING Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.885 | 0.914 | 0.70 | 0.7928627 | 65,628 | -0.0911 | -10.29% |
1 Month | 0.8494 | 1.16 | 0.70 | 0.9123187 | 77,554 | -0.0555 | -6.53% |
3 Months | 1.08 | 1.50 | 0.70 | 1.11 | 165,264 | -0.2861 | -26.49% |
6 Months | 6.052 | 12.70 | 0.70 | 5.16 | 912,742 | -5.26 | -86.88% |
1 Year | 19.00 | 21.80 | 0.70 | 7.59 | 601,439 | -18.21 | -95.82% |
3 Years | 100.00 | 103.00 | 0.70 | 18.96 | 406,677 | -99.21 | -99.21% |
5 Years | 100.00 | 103.00 | 0.70 | 18.96 | 406,677 | -99.21 | -99.21% |
Cingulate Description
Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. |